| Literature DB >> 30850614 |
Vanina Dengler Haunreiter1, Mathilde Boumasmoud1, Nicola Häffner1, Dennis Wipfli1, Nadja Leimer1,2, Carole Rachmühl1,3, Denise Kühnert1,4, Yvonne Achermann1, Reinhard Zbinden5, Stefano Benussi6, Clement Vulin7,8, Annelies S Zinkernagel9.
Abstract
Treatment failure in biofilm-associated bacterial infections is an important healthcare issue. In vitro studies and mouse models suggest that bacteria enter a slow-growing/non-growing state that results in transient tolerance to antibiotics in the absence of a specific resistance mechanism. However, little clinical confirmation of antibiotic tolerant bacteria in patients exists. In this study we investigate a Staphylococcus epidermidis pacemaker-associated endocarditis, in a patient who developed a break-through bacteremia despite taking antibiotics to which the S. epidermidis isolate is fully susceptible in vitro. Characterization of the clinical S. epidermidis isolates reveals in-host evolution over the 16-week infection period, resulting in increased antibiotic tolerance of the entire population due to a prolonged lag time until growth resumption and a reduced growth rate. Furthermore, we observe adaptation towards an increased biofilm formation capacity and genetic diversification of the S. epidermidis isolates within the patient.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30850614 PMCID: PMC6408453 DOI: 10.1038/s41467-019-09053-9
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 14.919
Fig. 1Overview of the clinical course, treatment, and S. epidermidis sampling. The antibiotic treatment scheme over the 16-week infection period. Surgical interventions and time points of S. epidermidis recovery are indicated. PM Pacemaker, ST sequence type
List of S. epidermidis isolates obtained from the patient over the infection period
| Isolate | ST | Phylogenetic group | Isolation week | Isolation material | Resistance profile |
|---|---|---|---|---|---|
| 1A | 378 | 1 | Week 1 | Deep wound extract pocket site infection | PEN, AMP, ERY |
| 1B | 378 | 1 | Week 1 | Deep wound extract pocket site infection | PEN, AMP, ERY |
| 1C | 378 | 1 | Week 1 | Tissue pocket site infection | PEN, AMP, ERY |
| 1D | 378 | 1 | Week 1 | Tissue pocket site infection | PEN, AMP, ERY |
| 1E | 378 | 1 | Week 1 | Electrode (inactive PM) | PEN, AMP, ERY |
| 1F | 378 | 1 | Week 1 | Electrode (inactive PM) | PEN, AMP, ERY |
| 14G | 378 | 2 | Week 14 | Blood culture | PEN, AMP, ERY |
| 16H | 378 | 2 | Week 16 | Electrode, n.s. | PEN, AMP, ERY, RIF |
| 16I | 378 | 2 | Week 16 | Pacemaker aggregate | PEN, AMP, ERY |
| 16J | 378 | 1 | Week 16 | Pacemaker aggregate | PEN, AMP, ERY |
| 16K | 378 | 2 | Week 16 | Right ventricular electrode | PEN, AMP, ERY, RIF |
| 16L | 378 | 2 | Week 16 | Right atrial electrode | PEN, AMP, ERY |
| 16M | 378 | 2 | Week 16 | Right ventricular electrode | PEN, AMP, ERY, RIF |
| 16N | 378 | 1 | Week 16 | Silicon caps of electrodes (inactive PM) | PEN, AMP, ERY |
| 16O | 378 | 2 | Week 16 | Right atrial electrode | PEN, AMP, ERY |
| 16P | 59 | n.a. | Week 16 | Pacemaker aggregate | PEN, AMP, ERY |
| 16Q | 88 | n.a. | Week 16 | Silicon caps of electrodes (inactive PM) | PEN, AMP |
| 16R | 88 | n.a. | Week 16 | Electrode, n.s. | PEN, AMP |
| 16S | 88 | n.a. | Week 16 | Electrode, n.s. | PEN, AMP |
| 16T | 88 | n.a. | Week 16 | Electrode, n.s. | PEN, AMP |
n.a. not applicable, n.s. not specified, PEN penicillin, AMP ampicillin, ERY erythromycin, RIF rifampicin, PM pacemaker, ST sequence type
Fig. 2Phylogenetic trees of the S. epidermidis isolates. a Midpoint-rooted maximum-likelihood tree based on the core-genes alignment of all the clinical isolates (ST59 purple, ST88 green, ST378 blue/red), and all complete S. epidermidis reference genomes available on NCBI (black, Supplementary Table 2). The scale bar indicates 0.002 SNPs per site. b Bayesian Evolutionary Analysis Sampling Trees (BEAST) phylogeny based on the ST378 isolates core gene SNPs alignment. The branch length in this tree is determined by the sampling time point. The branch coloring illustrates the estimated mutation rate (SNPs per site per year), whose range is indicated by the scale bar. Group I and group II isolates are indicated in blue and red, respectively. Dark red indicates the clinical isolate retrieved from the blood culture. The symbols (blue star, square, circle and triangle and red star, square and circle) label subclusters within the two main clusters. Denotations of these symbols can be found in the last column of Tables 2 and 3, to relate the mutations to the subcluster they were found in
Non-synonymous SNPs and InDels found in the group I clinical ST378 S. epidermidis isolates
| ID # | Gene name/function | Amino acid change | Isolates | Phylogenetic cluster |
|---|---|---|---|---|
| 1 | GraR, two-component response regulator | Gly59Arg | 1A, 1B, 1C, 1D, 1E, 1F, 16J, 16N | Group I |
| 2 | Sodium/di- and tricarboxylate cotransporter | Ser161stop | 1A, 1B, 1C, 1D, 1E, 1F, 16J, 16N | Group I |
| 3 | Cold-shock protein CspA | Gly57fs | 1A, 1B, 1C, 1D, 1E, 1F, 16J, 16N | Group I |
| 4 | RodA, rod shape-determining protein/FtsW, cell division protein | Gly161Val | 1A, 1B, 1C, 1D, 1E, 1F, 16J, 16N | Group I |
| 5 | PbuG, hypoxanthine/guanine permease | Ser27Leu | 1A, 1B, 1C, 1D, 1E, 1F, 16J, 16N | Group I |
| 6 | RpoB, DNA-directed RNA polymerase beta subunit | Arg917Leu | 1A, 1B, 1C, 1D, 1E, 1F, 16N | |
| 7 | Sle1, autolysin, N-acetylmuramoyl-L-alanine amidase | Val67Ala | 1A | |
| 8 | NrdI, ribonucleotide reduction protein | Arg14stop | 1A | |
| 9 | SecDF, protein translocase subunit | Ser621Asn | 1A | |
| 10 | Bicyclomycin-resistance protein TcaB/major myo-inositol transporter IolT | Pro64Ala | 1A | |
| 11 | ClpC, ATP-dependent Clp protease ATP-binding subunit | Arg12_Gln18del | 1B, 1E, 16N | Blue star |
| 12 | NrdI, ribonucleotide reduction protein | Glu112fs | 1B, 1E, 16N | Blue star |
| 13 | Isocitrate dehydrogenase | Val356Leu | 1B, 1E, 16N | Blue star |
| 14 | SufB, Fe-S cluster assembly protein | Ala129Gly | 1E | |
| 15 | peptidase, U32 family large subunit [C1] | Glu90Gln | 1E | |
| 17 | PrmA, ribosomal protein L11 methyltransferase | Asp107Gly | 1B, 16N | Blue square |
| 18 | Sialic acid utilization regulator, RpiR family/MurR/RpiR family transcriptional regulator | Val84Ile | 1B, 16N | Blue square |
| 19 | Two-component sensor kinase WalK | Met428Thr | 1B, 16N | Blue square |
| 20 | SarA, Staphylococcal accessory regulator A | Ala70Thr | 16N | |
| 21 | 3’-to-5’ oligoribonuclease A | Pro46fs | 16N | |
| 22 | acetate kinase | Thr239Ala | 16N | |
| 23 | Mqo, malate:quinone oxidoreductase | Ser431_Pro432_ Gly433_Ala434del | 16N | |
| 24 | Salicylate hydroxylase | Ala290Gly | 1C, 1D, 1F | Blue circle |
| 25 | Manganese ABC transporter, inner membrane permease protein SitD | Tyr243fs | 1C | |
| 26 | NrdI, ribonucleotide reduction protein | Gln54stop | 1C | |
| 27 | YrrC, RecD-like DNA helicase, deoxyribonuclease | Ile122Thr | 1C | |
| 28 | RpoC, DNA-directed RNA polymerase beta’ subunit | Gly433Val | 1D, 1F | Blue triangle |
| 29 | RibU, riboflavin transporter | Met1Val | 1D, 1F | Blue triangle |
| 30 | Iron-sulfur cluster assembly scaffold protein NifU | Lys134Glu | 1D | |
| 31 | PurR, pur operon repressor | Phe33Ser | 1F | |
| 32 | SrrB, respiratory response protein | Ile13Ser | 1F | |
| 33 | RpoB, DNA-directed RNA polymerase beta subunit | Gln137Pro | 16J | |
| 34 | Predicted RNA-binding protein, associated with RNAse of E/G family | Val15fs | 16J | |
| 35 | general stress protein 13 (contains ribosomal protein S1 (RPS1) domain) | Thr31fs | 16J | |
| 36 | Mqo, malate:quinone oxidoreductase | Arg375Trp | 16J | |
| 37 | PutP, proline/sodium symporter | Leu353stop | 1A, 1B, 1C, 1D, 1E, 1F, 16J, 16N, 14G, 16L,16O |
Non-synonymous mutations characteristic of all isolates, subclusters or single isolates from the group I phylogenetic cluster (labeled in blue in Fig. 2). The numbering in the first column is an identification number for each of the mutations reported (starting from 1 in Table 2, going up to 60 in Table 3). The isolates in which the mutations were found are given in the column “Isolates” and the symbols denotations in the “Phylogenetic cluster” column refer to the colored symbols shown on the phylogenetic tree branches to characterize subclusters (Fig. 2b). An extended version of this table, allowing a color-guided visualization and showing the mutations' localization in the S. epidermidis RP62A reference genome can be found in the Supplementary Information (Supplementary Table 3)
Non-synonymous SNPs and InDels found in the group II clinical ST378 S. epidermidis isolates
| ID # | Gene name/function | Amino acid change | Isolates | Phylogenetic cluster |
|---|---|---|---|---|
| 38 | Pta, phosphate acetyltransferase | Asp245Tyr | 14G, 16H,16I, 16K, 16L, 16M,16O | Group II |
| 39 | Penicillin-binding protein 1/Cell division protein FtsI | Val605Leu | 14G, 16H,16I, 16K, 16L, 16M,16O | Group II |
| 40 | RsbU, sigma factor B regulator | Thr325Asn | 14G, 16H,16I, 16K, 16L, 16M,16O | Group II |
| 41 | RNA-binding protein, conserved protein domain family EVE RNA binding | Trp17Cys | 14G, 16H,16I, 16K, 16L, 16M,16O | Group II |
| 42 | ArlR, two-component response regulator | Leu51fs | 14G, 16H,16I, 16K, 16L, 16M,16O | Group II |
| 43 | Mqo, malate:quinone oxidoreductase | Arg132stop | 14G, 16H,16I, 16K, 16L, 16M,16O | Group II |
| 44 | RpoB, DNA-directed RNA polymerase beta subunit | Gly491_Gly492 insProGly | 14G, 16L,16O | Red star |
| 45 | MsrC, free methionine-(R)-sulfoxide reductase | Gly64Asp | 14G, 16L,16O | Red star |
| 46 | Sat, sulfate adenylyltransferase | Pro348Gln | 14G, 16L,16O | Red star |
| 47 | pyruvate dehydrogenase subunit beta/branched-chain alpha-keto acid dehydrogenase E1 | Glu201Lys | 14G, 16L,16O | Red star |
| 48 | MprF virulence factor, phosphatidylglycerol lysyltransferase | Glu791_His792 insLeuGlu | 16L | |
| 49 | GTP-sensing transcriptional pleiotropic repressor CodY | Glu254fs | 16H, 16I, 16K, 16M | Red square |
| 50 | glycerol-3-phosphate responsive antiterminator | Gly129Ala | 16H, 16I, 16K, 16M | Red square |
| 51 | PrmA, ribosomal protein L11 methyltransferase | Glu238Ala | 16H, 16I, 16K, 16M | Red square |
| 52 | RpoB, DNA-directed RNA polymerase beta subunit | Gly492Val | 16I | |
| 53 | RelQ, (p)ppGpp synthetase | Phe40fs | 16I | |
| 54 | RSH, (p)ppGpp synthase/hydrolase | Leu533Phe | 16H, 16K, 16M | Red circle |
| 55 | RpoB, DNA-directed RNA polymerase beta subunit | Ala473_Asn474 insAla | 16H, 16K, 16M | Red circle |
| 56 | HssR, heme response regulator | Thr95Ala | 16H, 16K, 16M | Red circle |
| 57 | AgrA, accessory gene regulator protein A | Glu42fs | 16H | |
| 58 | Hypothetical serine protease | Arg78Ile | 16H | |
| 59 | AgrA, accessory gene regulator protein A | Arg218Pro | 16M | |
| 60 | L-Cystine ABC transporter, periplasmic cystine-binding protein TcyA | Thr45_Tyr46del | 16M |
Non-synonymous mutations characteristic of all isolates, subclusters or single isolates from the group II phylogenetic cluster (labeled in red in Fig. 2). The numbering in the first column is an identification number for each of the mutations reported (starting from 1 in Table 2, going up to 60 in Table 3). The isolates in which the mutations were found are given in the column “Isolates” and the symbols denotations in the “Phylogenetic cluster” column refer to the colored symbols shown on the phylogenetic tree branches to characterize subclusters (Fig. 2b). An extended version of this table, allowing a color-guided visualization and showing the mutations' localization in the S. epidermidis RP62A reference genome, can be found in the Supplementary Information (Supplementary Table 3)
Fig. 3Biofilm formation and hemolysis of the clinical ST378 isolates. a FEM pictures of the biofilm formed on the patient’s electrode. Scale bar left 5 µm and right 1 µm. b Quantitative in vitro biofilm assay of ST378 isolates. Isolates were grown in TSB 0.5% glucose in 96-well plates, and the washed biofilms were quantified by OD600 measurement. Statistical significance between the two groups was determined by Welch's t test (N = 60 t(46.40) = −10.513, P = 7.3 × 10-14). c Relative lysis of sheep blood erythrocytes by ST378 isolates indicated in percentages. The gray zone indicates the detection limit of 10% lysis below which the values were not included. Statistical significance between the two groups was determined by Welch's t test (N = 50 t(47.92) = 4.2857, P = 8.7 × 10-5). Group I and group II isolates are indicated in blue and red, respectively. Dark red indicates the clinical isolate retrieved from the blood culture. Averages with standard error of mean of at least three replicates are shown. ****P < 0.0001
Fig. 4Growth characteristics of ST378 isolates. a Growth curves of S. epidermidis isolates in the liquid TSB medium. The mean growth curve of three replicates is shown. Statistical significance of the time to reach OD 0.1 between the two groups was determined by Welch's t test (N = 46 t(29.96) = −5.0064, P = 2.295 × 10-5). b Colony size for the different isolates after 24 h growth on sheep blood plates. Scatter dot plot with averages and standard deviations of 89–182 colonies per isolate are shown. The gray zone corresponds to a colony radius < 100 µm, which was the detection limit of our setup. Statistical significance between the two groups was determined by Welch's t test (N = 1947 t(1587.8) = −19.634, P < 2 × 10−16). Group I and group II isolates are indicated in blue and red, respectively. Dark red indicates the clinical isolate retrieved from the blood culture. The red star refers to the monophyletic cluster formed by the three isolates with delayed growth curves and smallest colonies at 24 h. ****P < 0.0001
Fig. 5Macroscopic and microscopic analysis of the bacterial population’s growth kinetics. a Colony growth curves of bacteria obtained from stationary phase cultures and b biofilms. The gray zone corresponds to a colony radius < 100 µm, which is under the detection limit of the macroscopic time-lapse setup. Small insert graphs show the distribution of the radial colony growth rate (GR) in µm h−1 for the three isolates. Statistical significance between the three samples was determined by one way ANOVA (For the stationary: N = 182, F(2,179) = 488.7, P < 2 × 10−16, and Tukey’s post hoc test t14G-1A = −16.45, p14G-1A = 0, t16L-1A −12.47, p16L-1A = 0/biofilm: N = 237, F(2,234) = 311.8, P < 2 × 10-16 and Tukey’s post hoc test t14G-1A = −11.69, p14G-1A = 0, t16L-1A = −10.05, p16L-1A = 0). c Time to single cells’ first division. Curves show averages of three replicates and shaded areas depict standard deviation. The gray zone marks the period at the beginning of the experiment where cell divisions could occur, but not be observed. Group I and group II isolates are indicated in blue and red, respectively. Dark red indicates the clinical isolate retrieved from the blood culture. ****P < 0.0001
Fig. 6Antibiotic clearance of planktonically growing and biofilm-embedded bacteria. a Illustration of the assay used to determine the proportional killing of a bacteria population by antibiotics. b, c Ciprofloxacin killing of stationary growth phase bacteria. Bacteria were exposed to at least 40-fold MIC of ciprofloxacin for b 1.5, 3, 6, and 24 h and for c 3 and 24 h, respectively. The proportion of surviving bacteria relative to the inoculum was quantified by assessing the number of colony-forming units (CFUs) grown on agar plates. Curves and time points show averages of three replicates with standard deviation. Statistical significance of survival to 3 h antibiotic exposure between the two groups was determined by Welch's t test (N = 46 t(30.86) = −10.038, P = 3.069 × 10−11). A log scale representation is given in Supplementary Fig. 6a, b. d Illustration of the assay used to determine the antibiotic treatment efficiency of biofilms. Bacterial killing within a biofilm was measured by enumerating CFUs, and disruption of the biofilm was quantified by optical density after treatment with antibiotics. e Antibiotic killing of bacteria embedded within a biofilm by ciprofloxacin and a combination of ciprofloxacin and rifampicin as compared with stationary phase grown bacteria (same data points as shown in b). The proportion of surviving bacteria relative to the bacteria recovered from the pre-grown biofilm was quantified by assessing the number of CFUs grown on agar plates. Averages with standard deviation of three replicates are shown. A log scale representation is given in Supplementary Fig. 6c. f Quantitative in vitro biofilm assays of untreated, ciprofloxacin, and a combination of ciprofloxacin- and rifampicin-treated biofilm. Biofilms were quantified by OD600 measurement. Averages with standard error of mean of three replicates are shown. Group I and group II isolates are indicated in blue and red, respectively. Dark red indicates the clinical isolate retrieved from the blood culture. ****P < 0.0001